Table 3.
HRs for cause-specific mortality by diabetes status at CRC diagnosis.
| Cause of death | Women | Men | Combined | |||
|---|---|---|---|---|---|---|
| No diabetes | Diabetes | No diabetes | Diabetes | No diabetes | Diabetes | |
| No. of patients | 2349 | 284 | 1260 | 145 | 3609 | 429 |
| CRC | ||||||
| No. of deaths | 865 | 107 | 433 | 45 | 1298 | 152 |
| Age-adjusted HR (95% CI) | 1 | 1.19 (0.97–1.45) | 1 | 0.85 (0.63–1.16) | 1 | 1.07 (0.90–1.27) |
| Multivariate HR (95% CI)a | 1 | 1.24 (1.01–1.52) | 1 | 0.89 (0.65–1.23) | 1 | 1.11 (0.94–1.32) |
| Multivariate HR (95% CI)b | 1 | 1.21 (0.98–1.49) | 1 | 0.88 (0.64–1.21) | 1 | 1.09 (0.91–1.30)c |
| Other malignancies | ||||||
| No. of deaths | 142 | 23 | 72 | 7 | 214 | 30 |
| Age-adjusted HR (95% CI) | 1 | 2.02 (1.29–3.15) | 1 | 1.06 (0.49–2.34) | 1 | 1.67 (1.13–2.45) |
| Multivariate HR (95% CI)a | 1 | 2.00 (1.27–3.13) | 1 | 1.18 (0.52–2.63) | 1 | 1.69 (1.14–2.50) |
| Multivariate HR (95% CI)b | 1 | 2.15 (1.34–3.46) | 1 | 1.28 (0.56–2.91) | 1 | 1.78 (1.18–2.67)c |
| Cardiovascular disease | ||||||
| No. of deaths | 62 | 13 | 126 | 18 | 188 | 31 |
| Age-adjusted HR (95% CI) | 1 | 2.61 (1.42–4.81) | 1 | 1.60 (0.96–2.66) | 1 | 1.88 (1.27–2.77) |
| Multivariate HR (95% CI)a | 1 | 2.70 (1.46–4.99) | 1 | 1.88 (1.10–3.21) | 1 | 2.19 (1.46–3.26) |
| Multivariate HR (95% CI)b | 1 | 1.94 (1.01–3.73) | 1 | 1.82 (1.07–3.12) | 1 | 1.93 (1.29–2.91)c |
Stratified by sex (in women and men combined) and cancer stage (I to IV or unknown) and adjusted for age at cancer diagnosis (continuous), race (White, nonwhite, or unknown), grade of tumor differentiation (well differentiated, moderately differentiated, poorly differentiated, or unknown), location of primary tumor (proximal colon, distal colon, rectum, or unknown), and year of diagnosis (continuous).
Additionally adjusted for body mass index (continuous), physical activity (continuous), smoking status (never, past, or current), alcohol intake (continuous), AHEI-2010 (continuous), and regular aspirin use (yes or no).
P heterogeneity by sex = 0.10, 0.28, and 0.88 for mortality from CRC, other malignancies, and cardiovascular disease, respectively.